

## References

I-124

1. Navada SC and Silverman LR. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes. *Ther Adv Hematol*. 2017; 8(1):21-27.
2. Murakami K, Ueno H, Okabe T, Kagoo T, Boku S, Yano T, et al. Bridging-to-transplant with azacitidine for myelodysplastic syndrome and acute myeloid leukemia, reduces the incidence of acute graft-versus-host disease. *Hematology Reports*. 2017; 9:78-80.
3. Shapiro RM and Lazo-Langer A. Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. *BMC Hematology*. 2018;18(3):1-9.
4. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukemia: Comparison of French-American-British and World Health Organization classifications. *Journ of Hemat & Onc*. 2016; 9(39):1-16.
5. National Comprehensive Cancer Network (NCCN). Azacitidine. NCCN Drugs and Biologics Compendium® 2024.
6. Vidaza (azacitidine for injection), for subcutaneous or intravenous use [package insert]. Celgene Corporation. Summit, NJ. Revised 01/2024.
7. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Azacitidine.
8. Micromedex DrugDex Compendium®.-2024. Azacitidine.
9. Laribi K, Bolle D, Alani M, Ghnaya H, Besancon, A. et al. Impact of the relative dose intensity on survival of patients with high-risk myelodysplastic syndromes treated with Azacitidine. *Cancer Medicine*. 2019; 2188-2195.
10. Komrokji R, Swern AS, Grinblatt D, et al. Azacitidine in lower-risk myelodysplastic syndromes: a meta-analysis of data from prospective studies. *Oncologist*. 2018;23(2):159-170.
11. Stahl M, Bewersdorf JP, Giri S, Rong Wang, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. *Haematologica*. 2020;105(1):102-111.
12. Fenaux P, Platzbecker U, Mufti GJ, et al. Luspatercept in patients with lower-risk myelodysplastic syndromes. *N Eng J Med*.2020;382:140-151.
13. Azacitidine. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated May 11, 2011.
14. Niemeyer CM, Flotho C, Lipka DB, et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. *Blood Adv*. 2021;5(14):2901-2908.